T1	tradename 0 9	Krystexxa
T3	nanoparticle 11 23	pegloticase)
T5	tradename 146 155	KRYSTEXXA
T7	tradename 219 239	KRYSTEXXA KRYSTEXXA
T9	nanoparticle 241 253	pegloticase)
T11	routeofadministration 269 280	intravenous
T13	fdaapprovaldate 313 317	2010
T15	adversereaction 328 339	ANAPHYLAXIS
T17	adversereaction 344 362	INFUSION REACTIONS
T19	tradename 427 427	
T21	adversereaction 427 438	Anaphylaxis
T23	adversereaction 443 461	infusion reactions
T25	tradename 525 534	KRYSTEXXA
T27	tradename 548 557	KRYSTEXXA
T29	adversereaction 652 663	anaphylaxis
T31	adversereaction 668 687	infusion reactions.
T33	co-administereddrug 728 742	antihistamines
T35	co-administereddrug 747 763	corticosteroids.
T37	adversereaction 840 851	anaphylaxis
T39	tradename 876 889	KRYSTEXXA. 
T41	adversereaction 1186 1197	Anaphylaxis
T43	adversereaction 1238 1255	Infusion Reaction
T45	tradename 1343 1352	KRYSTEXXA
T47	nanoparticle 1354 1366	pegloticase)
T49	surfacecoating 1372 1381	PEGylated
T51	activeingredient 1382 1417	uric acid specific enzyme indicated
T53	indication 1439 1451	chronic gout
T55	tradename 1542 1551	KRYSTEXXA
T57	dose 1712 1716	8 mg
T59	routeofadministration 1729 1740	intravenous
T61	frequency 1750 1766	every two weeks.
T63	routeofadministration 1798 1809	intravenous
T65	routeofadministration 1844 1848	oral
T67	tradename 1887 1896	KRYSTEXXA
T69	co-administereddrug 2002 2016	antihistamines
T71	co-administereddrug 2021 2037	corticosteroids.
T73	adversereaction 2133 2145	anaphylaxis.
T75	tradename 2167 2176	KRYSTEXXA
T77	routeofadministration 2218 2229	intravenous
T79	dose 2444 2448	8 mg
T81	nanoparticle 2452 2463	pegloticase
T83	activeingredient 2486 2493	uricase
T85	tradename 2660 2669	KRYSTEXXA
T87	tradename 2909 2909	
T89	adversereaction 2909 2933	Anaphylaxis: Anaphylaxis
T91	tradename 2968 2980	KRYSTEXXA. 
T93	adversereaction 2980 2991	Anaphylaxis
T95	adversereaction 3128 3154	hypersensitivity reactions
T97	tradename 3182 3191	KRYSTEXXA
T99	adversereaction 3285 3297	anaphylaxis.
T101	co-administereddrug 3338 3352	antihistamines
T103	co-administereddrug 3357 3373	corticosteroids.
T105	adversereaction 3451 3462	anaphylaxis
T107	tradename 3487 3497	KRYSTEXXA.
T109	tradename 3504 3504	
T111	adversereaction 3504 3543	Infusion Reactions: Infusion reactions
T113	tradename 3578 3600	KRYSTEXXA. KRYSTEXXA
T115	adversereaction 3695 3714	infusion reactions.
T117	co-administereddrug 3754 3768	antihistamines
T119	co-administereddrug 3773 3789	corticosteroids.
T121	adversereaction 3843 3862	infusion reactions.
T123	adversereaction 3883 3900	infusion reaction
T125	adversereaction 4087 4104	infusion reaction
T127	tradename 4171 4171	
T129	adversereaction 4171 4183	Gout Flares:
T131	adversereaction 4199 4210	gout flares
T133	tradename 4306 4318	KRYSTEXXA. 
T135	adversereaction 4323 4333	gout flare
T137	tradename 4359 4368	KRYSTEXXA
T139	tradename 4396 4396	
T141	adversereaction 4396 4406	Gout flare
T143	co-administereddrug 4426 4471	non-steroidal anti-inflammatory drugs [NSAID]
T145	co-administereddrug 4475 4485	colchicine
T147	tradename 4632 4632	
T149	adversereaction 4632 4657	Congestive Heart Failure:
T151	tradename 4658 4667	KRYSTEXXA
T153	adversereaction 4715 4739	congestive heart failure
T155	tradename 4834 4843	KRYSTEXXA
T157	adversereaction 4865 4889	congestive heart failure
T159	tradename 5084 5101	KRYSTEXXA-treated
T161	adversereaction 5116 5127	gout flares
T163	adversereaction 5129 5147	infusion reactions
T165	adversereaction 5149 5155	nausea
T167	adversereaction 5157 5166	contusion
T169	adversereaction 5170 5180	ecchymosis
T171	adversereaction 5182 5197	nasopharyngitis
T173	adversereaction 5199 5211	constipation
T175	adversereaction 5213 5223	chest pain
T177	adversereaction 5225 5236	anaphylaxis
T179	adversereaction 5241 5250	vomiting.
T181	company 5305 5328	Savient Pharmaceuticals
T183	company 5330 5334	Inc.
T185	tradename 5360 5370	KRYSTEXXA)
T187	adversereaction 5558 5569	ANAPHYLAXIS
T189	adversereaction 5574 5592	INFUSION REACTIONS
T191	adversereaction 5778 5789	Anaphylaxis
T193	adversereaction 5795 5813	Infusion Reactions
T195	adversereaction 5819 5830	Gout Flares
T197	adversereaction 5836 5860	Congestive Heart Failure
T199	tradename 5884 5896	KRYSTEXXA 
T201	adversereaction 6496 6507	Anaphylaxis
T203	adversereaction 6512 6530	Infusion Reactions
T205	adversereaction 6596 6607	Gout Flares
T207	adversereaction 6736 6747	ANAPHYLAXIS
T209	adversereaction 6752 6770	INFUSION REACTIONS
T211	tradename 6772 6772	
T213	adversereaction 6772 6783	Anaphylaxis
T215	adversereaction 6788 6806	infusion reactions
T217	tradename 6870 6880	KRYSTEXXA.
T219	tradename 6924 6924	
T221	adversereaction 6924 6935	Anaphylaxis
T223	adversereaction 7073 7099	hypersensitivity reactions
T225	tradename 7126 7135	KRYSTEXXA
T227	adversereaction 7229 7240	anaphylaxis
T229	adversereaction 7245 7264	infusion reactions.
T231	co-administereddrug 7303 7317	antihistamines
T233	co-administereddrug 7322 7338	corticosteroids.
T235	adversereaction 7415 7426	anaphylaxis
T237	tradename 7451 7462	KRYSTEXXA. 
T239	tradename 7680 7689	KRYSTEXXA
T241	nanoparticle 7691 7703	pegloticase)
T243	surfacecoating 7709 7718	PEGylated
T245	activeingredient 7719 7744	uric acid specific enzyme
T247	indication 7776 7788	chronic gout
T249	tradename 8156 8165	KRYSTEXXA
T251	tradename 8314 8323	KRYSTEXXA
T253	dose 8346 8350	8 mg
T255	activeingredient 8352 8359	uricase
T257	routeofadministration 8381 8401	intravenous infusion
T259	tradename 8456 8465	KRYSTEXXA
T261	tradename 8529 8538	KRYSTEXXA
T263	tradename 8772 8781	KRYSTEXXA
T265	routeofadministration 9002 9013	intravenous
T267	tradename 9111 9120	KRYSTEXXA
T269	tradename 9191 9200	KRYSTEXXA
T271	tradename 9570 9579	KRYSTEXXA
T273	tradename 9609 9618	KRYSTEXXA
T275	routeofadministration 9638 9649	intravenous
T277	routeofadministration 9789 9800	intravenous
T279	tradename 9856 9865	KRYSTEXXA
T281	routeofadministration 9887 9891	oral
T283	routeofadministration 9950 9954	oral
T285	tradename 9999 10008	KRYSTEXXA
T287	adversereaction 10051 10062	anaphylaxis
T289	adversereaction 10067 10085	infusion reactions
T291	tradename 10383 10392	KRYSTEXXA
T293	routeofadministration 10434 10445	intravenous
T295	co-administereddrug 10596 10610	antihistamines
T297	co-administereddrug 10612 10628	corticosteroids)
T299	adversereaction 10654 10665	anaphylaxis
T301	adversereaction 10670 10689	infusion reactions.
T303	tradename 10702 10711	KRYSTEXXA
T305	adversereaction 10783 10794	anaphylaxis
T307	adversereaction 10799 10817	infusion reactions
T309	adversereaction 10945 10962	infusion reaction
T311	tradename 10999 11008	KRYSTEXXA
T313	tradename 11363 11372	KRYSTEXXA
T315	nanoparticle 11424 11435	pegloticase
T317	activeingredient 11487 11494	uricase
T319	tradename 11506 11515	KRYSTEXXA
T321	tradename 11622 11631	KRYSTEXXA
T323	tradename 11907 11920	KRYSTEXXA.  
T325	adversereaction 11953 11964	Anaphylaxis
T327	adversereaction 12016 12027	anaphylaxis
T329	tradename 12091 12100	KRYSTEXXA
T331	frequency 12101 12114	every 2 weeks
T333	adversereaction 12172 12180	wheezing
T335	adversereaction 12182 12208	peri-oral or lingual edema
T337	adversereaction 12213 12236	hemodynamic instability
T339	adversereaction 12254 12258	rash
T341	adversereaction 12262 12272	urticaria.
T343	routeofadministration 12348 12352	oral
T345	co-administereddrug 12353 12366	antihistamine
T347	routeofadministration 12371 12382	intravenous
T349	co-administereddrug 12383 12397	corticosteroid
T351	co-administereddrug 12405 12419	acetaminophen.
T353	adversereaction 12490 12501	anaphylaxis
T355	tradename 12593 12602	KRYSTEXXA
T357	adversereaction 12693 12705	anaphylaxis.
T359	tradename 12779 12779	
T361	adversereaction 12779 12790	Anaphylaxis
T363	adversereaction 12926 12952	hypersensitivity reactions
T365	adversereaction 13054 13065	anaphylaxis
T367	tradename 13090 13103	KRYSTEXXA. 
T369	adversereaction 13225 13236	anaphylaxis
T371	adversereaction 13301 13312	anaphylaxis
T373	routeofadministration 13629 13633	oral
T375	tradename 13661 13670	KRYSTEXXA
T377	tradename 13768 13777	KRYSTEXXA
T379	routeofadministration 13799 13803	oral
T381	routeofadministration 13862 13866	oral
T383	tradename 13902 13915	KRYSTEXXA.  
T385	adversereaction 13919 13937	Infusion Reactions
T387	tradename 13938 13938	
T389	adversereaction 13938 13944	During
T391	tradename 14052 14061	KRYSTEXXA
T393	dose 14062 14066	8 mg
T395	frequency 14067 14080	every 2 weeks
T397	tradename 14115 14124	KRYSTEXXA
T399	dose 14125 14129	8 mg
T401	frequency 14130 14143	every 4 weeks
T403	adversereaction 14201 14219	infusion reactions
T405	routeofadministration 14267 14271	oral
T407	co-administereddrug 14272 14285	antihistamine
T409	routeofadministration 14287 14298	intravenous
T411	co-administereddrug 14299 14313	corticosteroid
T413	co-administereddrug 14321 14335	acetaminophen.
T415	adversereaction 14406 14424	infusion reactions
T417	tradename 14516 14525	KRYSTEXXA
T419	adversereaction 14616 14635	infusion reactions.
T421	co-administereddrug 14673 14687	antihistamines
T423	co-administereddrug 14692 14708	corticosteroids.
T425	tradename 14710 14719	KRYSTEXXA
T427	adversereaction 14796 14813	infusion reaction
T429	tradename 15267 15276	KRYSTEXXA
T431	tradename 15374 15383	KRYSTEXXA
T433	tradename 15508 15521	KRYSTEXXA.  
T435	adversereaction 15525 15536	Gout Flares
T437	tradename 15537 15537	
T439	adversereaction 15537 15548	Gout flares
T441	tradename 15579 15589	KRYSTEXXA.
T443	adversereaction 15636 15647	gout flares
T445	tradename 15815 15815	
T447	adversereaction 15815 15825	Gout flare
T449	co-administereddrug 15845 15889	non-steroidal anti-inflammatory drug (NSAID)
T451	co-administereddrug 15893 15903	colchicine
T453	tradename 15965 15974	KRYSTEXXA
T455	tradename 16065 16074	KRYSTEXXA
T457	adversereaction 16266 16290	Congestive Heart Failure
T459	tradename 16292 16301	KRYSTEXXA
T461	adversereaction 16349 16373	congestive heart failure
T463	tradename 16501 16510	KRYSTEXXA
T465	adversereaction 16532 16556	congestive heart failure
T467	tradename 16629 16640	KRYSTEXXA 
T469	tradename 16727 16736	KRYSTEXXA
T471	tradename 16817 16826	KRYSTEXXA
T473	adversereaction 16888 16899	anaphylaxis
T475	adversereaction 16904 16923	infusion reactions.
T477	adversereaction 17183 17194	anaphylaxis
T479	tradename 17259 17268	KRYSTEXXA
T481	dose 17269 17273	8 mg
T483	frequency 17274 17287	every 2 weeks
T485	adversereaction 17320 17338	infusion reactions
T487	tradename 17402 17411	KRYSTEXXA
T489	dose 17412 17416	8 mg
T491	frequency 17417 17430	every 2 weeks
T493	adversereaction 17473 17484	gout flares
T495	tradename 17553 17562	KRYSTEXXA
T497	routeofadministration 17669 17673	oral
T499	co-administereddrug 17674 17687	antihistamine
T501	routeofadministration 17689 17700	intravenous
T503	co-administereddrug 17701 17715	corticosteroid
T505	co-administereddrug 17723 17736	acetaminophen
T507	adversereaction 17748 17759	anaphylaxis
T509	adversereaction 17764 17782	infusion reaction.
T511	co-administereddrug 17807 17844	non-steroidal anti-inflammatory drugs
T513	co-administereddrug 17848 17858	colchicine
T515	adversereaction 17892 17902	gout flare
T517	tradename 17932 17941	KRYSTEXXA
T519	tradename 18094 18103	KRYSTEXXA
T521	indication 18121 18133	chronic gout
T523	tradename 18286 18295	KRYSTEXXA
T525	dose 18296 18300	8 mg
T527	tradename 18346 18355	KRYSTEXXA
T529	dose 18356 18360	8 mg
T531	tradename 19468 19477	KRYSTEXXA
T533	tradename 19664 19676	KRYSTEXXA. 
T535	tradename 19811 19823	KRYSTEXXA. 
T537	tradename 21631 21640	KRYSTEXXA
T539	tradename 21736 21745	KRYSTEXXA
T541	tradename 21957 21966	KRYSTEXXA
T543	dose 21967 21971	8 mg
T545	tradename 21987 21996	KRYSTEXXA
T547	dose 21997 22001	8 mg
T549	tradename 22144 22153	KRYSTEXXA
T551	dose 22154 22158	8 mg
T553	tradename 22174 22183	KRYSTEXXA
T555	dose 22184 22188	8 mg
T557	tradename 22386 22396	KRYSTEXXA.
T559	tradename 22435 22436	 
T561	adversereaction 22436 22461	Congestive Heart Failure:
T563	tradename 22578 22587	KRYSTEXXA
T565	dose 22588 22592	8 mg
T567	frequency 22593 22607	every 2 weeks.
T569	tradename 22750 22759	KRYSTEXXA
T571	dose 22760 22764	8 mg
T573	frequency 22765 22778	every 2 weeks
T575	tradename 22999 23008	KRYSTEXXA
T577	dose 23009 23012	8mg
T579	frequency 23013 23026	every 2 weeks
T581	tradename 23129 23138	KRYSTEXXA
T583	tradename 23178 23187	KRYSTEXXA
T585	tradename 23214 23214	
T587	adversereaction 23214 23224	Gout flare
T589	tradename 23226 23226	
T591	dose 23226 23230	8 mg
T593	frequency 23231 23244	every 2 weeks
T595	tradename 23291 23291	
T597	adversereaction 23291 23308	Infusion reaction
T599	tradename 23326 23326	
T601	adversereaction 23326 23343	Nausea Contusionb
T603	adversereaction 23347 23358	Ecchymosisb
T605	tradename 23391 23391	
T607	adversereaction 23391 23406	Nasopharyngitis
T609	tradename 23422 23422	
T611	adversereaction 23422 23434	Constipation
T613	tradename 23450 23450	
T615	adversereaction 23450 23460	Chest Pain
T617	tradename 23476 23476	
T619	adversereaction 23476 23487	Anaphylaxis
T621	tradename 23503 23503	
T623	adversereaction 23503 23511	Vomiting
T625	adversereaction 23798 23807	contusion
T627	adversereaction 23811 23821	ecchymosis
T629	tradename 23952 23961	KRYSTEXXA
T631	frequency 23962 23975	every 2 weeks
T633	tradename 24070 24082	KRYSTEXXA. 
T635	nanoparticle 24161 24180	pegloticase-induced
T637	adversereaction 24350 24368	infusion reactions
T639	tradename 24446 24455	KRYSTEXXA
T641	frequency 24456 24469	every 2 weeks
T643	nanoparticle 24955 24966	pegloticase
T645	tradename 25091 25100	KRYSTEXXA
T647	surfacecoating 25199 25202	PEG
T649	tradename 25639 25651	KRYSTEXXA. 
T651	tradename 25675 25684	KRYSTEXXA
T653	tradename 25852 25861	KRYSTEXXA
T655	tradename 25919 25919	
T657	nanoparticle 25919 25930	Pegloticase
T659	dose 25972 25973	0
T661	dose 25975 25976	5
T663	dose 25978 25980	10
T665	dose 25982 25993	or 40 mg/kg
T667	frequency 25994 26006	twice weekly
T669	routeofadministration 26014 26025	intravenous
T671	dose 26167 26171	8 mg
T673	dose 26173 26184	0.133 mg/kg
T675	frequency 26210 26223	every 2 weeks
T677	tradename 26498 26507	KRYSTEXXA
T679	tradename 26582 26591	KRYSTEXXA
T681	tradename 26733 26742	KRYSTEXXA
T683	dose 26743 26747	8 mg
T685	frequency 26748 26761	every 2 weeks
T687	tradename 27269 27278	KRYSTEXXA
T689	dose 27279 27283	8 mg
T691	frequency 27284 27297	every 2 weeks
T693	tradename 27438 27447	KRYSTEXXA
T695	routeofadministration 27525 27536	intravenous
T697	dose 27545 27550	12 mg
T699	activeingredient 27554 27561	uricase
T701	tradename 27755 27764	KRYSTEXXA
T703	nanoparticle 27766 27778	pegloticase)
T705	activeingredient 27784 27809	uric acid specific enzyme
T707	surfacecoating 27821 27830	PEGylated
T709	activeingredient 27887 27900	urate oxidase
T711	activeingredient 27902 27910	uricase)
T713	tradename 27975 27975	
T715	activeingredient 27975 27982	Uricase
T717	surfacecoating 28011 28050	monomethoxypoly(ethylene glycol) [mPEG]
T719	molecularweight 28052 28058	10 kDa
T721	molecularweight 28205 28211	34 kDa
T723	nanoparticle 28258 28269	pegloticase
T725	activeingredient 28271 28288	tetrameric enzyme
T727	surfacecoating 28303 28308	mPEG)
T729	molecularweight 28326 28334	540 kDa.
T731	tradename 28336 28345	KRYSTEXXA
T733	routeofadministration 28362 28373	intravenous
T735	tradename 28385 28394	KRYSTEXXA
T737	nanoparticle 28454 28465	pegloticase
T739	tradename 28497 28506	KRYSTEXXA
T741	nanoparticle 28508 28520	pegloticase)
T743	tradename 28599 28608	KRYSTEXXA
T745	dose 28618 28622	8 mg
T747	activeingredient 28626 28633	uricase
T749	molecularweight 28666 28672	10 kDa
T751	surfacecoating 28673 28678	mPEG)
T753	inactiveingredient 28688 28740	Disodium Hydrogen Phosphate Dihydrate (Na2HPO4 2H2O)
T755	inactiveingredient 28750 28772	Sodium Chloride (NaCl)
T757	inactiveingredient 28782 28843	Sodium Dihydrogen Phosphate Dihydrate (NaH2PO4 &#x20ac; 2H2O)
T759	inactiveingredient 28849 28854	Water
T761	dose 28880 28884	8 mg
T763	nanoparticle 28888 28899	pegloticase
T765	activeingredient 28904 28911	uricase
T767	tradename 28977 28986	KRYSTEXXA
T769	activeingredient 28992 29017	uric acid specific enzyme
T771	activeingredient 29041 29048	uricase
T773	tradename 29369 29378	KRYSTEXXA
T775	tradename 29429 29438	KRYSTEXXA
T777	tradename 29469 29478	KRYSTEXXA
T779	dose 29479 29483	8 mg
T781	routeofadministration 29646 29657	intravenous
T783	dose 29671 29674	0.5
T785	dose 29676 29677	1
T787	dose 29679 29680	2
T789	dose 29682 29683	4
T791	dose 29685 29695	8 or 12 mg
T793	nanoparticle 29699 29710	pegloticase
T795	indication 29731 29747	symptomatic gout
T797	dose 30100 30104	8 mg
T799	dose 30109 30115	12 mg.
T801	tradename 30142 30142	
T803	nanoparticle 30142 30153	Pegloticase
T805	activeingredient 30211 30218	uricase
T807	routeofadministration 30254 30265	intravenous
T809	dose 30279 30285	0.5 mg
T811	dose 30289 30294	12 mg
T813	nanoparticle 30295 30306	pegloticase
T815	indication 30327 30343	symptomatic gout
T817	nanoparticle 30377 30388	pegloticase
T819	nanoparticle 30577 30589	pegloticase.
T821	nanoparticle 30782 30793	pegloticase
T823	nanoparticle 30943 30954	pegloticase
T825	routeofadministration 31343 31354	intravenous
T827	tradename 32605 32614	KRYSTEXXA
T829	indication 32650 32662	chronic gout
T831	tradename 32866 32875	KRYSTEXXA
T833	dose 32876 32880	8 mg
T835	frequency 32881 32894	every 2 weeks
T837	frequency 32898 32911	every 4 weeks
T839	tradename 33319 33328	KRYSTEXXA
T841	tradename 34187 34196	KRYSTEXXA
T843	tradename 34467 34476	KRYSTEXXA
T845	frequency 34477 34490	every 2 weeks
T847	frequency 34579 34593	4 week regimen
T849	adversereaction 34703 34714	anaphylaxis
T851	adversereaction 34719 34737	infusion reactions
T853	dose 35002 35006	8 mg
T855	frequency 35007 35020	every 2 weeks
T857	dose 35069 35073	8 mg
T859	frequency 35074 35087	every 4 weeks
T861	dose 35157 35161	8 mg
T863	frequency 35162 35175	every 2 weeks
T865	dose 35223 35227	8 mg
T867	frequency 35228 35241	every 4 weeks
T869	tradename 35537 35546	KRYSTEXXA
T871	tradename 35838 35847	KRYSTEXXA
T873	tradename 36618 36627	KRYSTEXXA
T875	dose 36628 36632	8 mg
T877	frequency 36633 36646	every 2 weeks
T879	tradename 36648 36657	KRYSTEXXA
T881	dose 36658 36662	8 mg
T883	frequency 36663 36676	every 4 weeks
T885	tradename 36729 36738	KRYSTEXXA
T887	frequency 36789 36801	every 2 week
T889	frequency 36834 36846	every 4 week
T891	tradename 36916 36925	KRYSTEXXA
T893	routeofadministration 37020 37031	intravenous
T895	tradename 37058 37067	KRYSTEXXA
T897	tradename 37179 37188	KRYSTEXXA
T899	dose 37192 37196	8 mg
T901	tradename 37287 37296	KRYSTEXXA
T903	adversereaction 37745 37756	Anaphylaxis
T905	adversereaction 37761 37779	Infusion Reactions
T907	tradename 37781 37781	
T909	adversereaction 37781 37792	Anaphylaxis
T911	adversereaction 37797 37815	infusion reactions
T913	adversereaction 38045 38056	anaphylaxis
T915	adversereaction 38068 38076	wheezing
T917	adversereaction 38078 38104	peri-oral or lingual edema
T919	adversereaction 38106 38129	hemodynamic instability
T921	adversereaction 38135 38139	rash
T923	adversereaction 38143 38153	urticaria.
T925	adversereaction 38216 38233	infusion reaction
T927	adversereaction 38245 38254	urticaria
T929	adversereaction 38268 38276	erythema
T931	adversereaction 38300 38307	dyspnea
T933	adversereaction 38332 38340	flushing
T935	adversereaction 38342 38358	chest discomfort
T937	adversereaction 38360 38370	chest pain
T939	adversereaction 38376 38381	rash.
T941	tradename 38533 38543	KRYSTEXXA.
T943	tradename 38693 38702	KRYSTEXXA
T945	tradename 38759 38771	KRYSTEXXA. 
T947	tradename 38856 38865	KRYSTEXXA
T949	tradename 39264 39273	KRYSTEXXA
T951	tradename 39380 39389	KRYSTEXXA
T953	tradename 39506 39515	KRYSTEXXA
T955	tradename 39565 39565	
T957	company 39565 39588	Savient Pharmaceuticals
T959	company 39590 39594	Inc.
